Thomas J. Dee

Chief Executive Officer, Endsulin Inc.

Thomas J. Dee is Chief Executive Officer of Endsulin Inc., a pre-clinical gene therapy company dedicated to developing a treatment for Type 1 Diabetes Mellitus.  Prior to Endsulin, he was Senior Vice President, Chief Financial Officer, AveXis, Inc., a gene therapy company that successfully developed a treatment for Spinal Muscular Atrophy, marketed by Novartis as Zolgensma.  Prior to joining AveXis, Mr. Dee was an independent business development consultant to early-stage companies. Mr. Dee spent 24 years of his career at Abbott Laboratories Inc., where he held a number of senior management positions, including vice president, international finance operations, vice president, controller of pharmaceutical products, vice president, controller of Abbott International, and vice president, internal audit. Mr. Dee also serves or has served as director of several companies and educational institutes. Mr. Dee earned a B.A. from Northern Illinois University and an M.B.A. from the Kellogg School of Management at Northwestern University and is a Certified Public Accountant.